Helixmith Co., Ltd

A084990

KR7084990001

Food Processing

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
3,440 ^KRW	-0.15%		-1.43%	-44.25%

04-25	Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding	CI
02-05	Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding	CI

Helixmith Co., Ltd announced that it has received KRW 20 billion in funding

January 21, 2021

On January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction.

Latest news about Helixmith Co., Ltd

Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding	04-24	CI
Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding	02-04	CI
Helixmith Stock Plummets Following Clinical Setback in Gene Therapy Candidate	01-04	MT
Helixmith Co., Ltd announced that it has received KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	12-27	CI
Helixmith Co., Ltd announced that it expects to receive KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	12-19	CI
Helixmith Co., Ltd announced that it has received KRW 19.999986156 billion in funding from CANARIABIO M Inc.	23-08-30	CI
Helixmith Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Helixmith Co., Ltd announces tranche update	23-02-14	CI
Helixmith Co., Ltd announced that it expects to receive KRW 19.999986156 billion in funding from CANARIABIO M Inc.	23-02-06	CI
Helixmith Co., Ltd announced that it has received KRW 34.99999386 billion in funding from CANARIABIO M Inc.	22-12-28	CI
Sejong Medical Co., Ltd. announced that it has received KRW 30 billion in funding from Helixmith Co., Ltd	22-12-28	CI
South Korean Stocks Decline Nearly 2% over Rate Hike Fears in the US; Samsung Loses 2%	22-12-23	MT
Helixmith to Raise 35 Billion Won From Stock Sale; Shares Decline 7%	22-12-22	MT
Helixmith Co., Ltd announced that it expects to receive KRW 34.99999386 billion in funding from CANARIABIO M Inc.	22-12-20	CI
Sejong Medical Co., Ltd. announced that it expects to receive KRW 30 billion in funding from Helixmith Co., Ltd	22-12-20	CI
Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index	22-09-19	CI
Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)	22-09-06	CI
Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19	22-08-03	CI
Paper Reporting Results from Helixmith's Phase 3 Gene Therapy Trial for Painful Diabetic Neuropathy was One of the Top-10 Most-Downloaded Articles in Clinical and Translational Science	22-03-14	CI
Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS	21-12-01	CI
Helixmith Co. Ltd Announces Positive Topline Data from World's First Gene Therapy Phase 1 Study for CMT	21-11-09	CI
Helixmith Announces Phase 3 Study Results of Novel Gene Therapy Treatment for Diabetic Foot Ulcers At 2021 Annual Meeting of Diabetic Foot Ulcer Conference	21-10-22	CI
Helixmith to Step into CDMO Market with Gene, Cellular Therapy in 2022	21-09-17	MT
Wacker Chemie AG completed the acquisition of Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd.	21-02-27	CI
Wacker Chemie AG entered into an agreement to acquire Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd for $42 million.	21-02-01	CI

Helixmith Co Ltd, formerly ViroMed Co Ltd, is a Korea-based company mainly engaged in the development and sales of natural medicines and health functional foods. The Company operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.

Sector

Food Processing

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
HELIXMITH CO., LTD	-44.25%	115M
ZHEJIANG NHU COMPANY LTD.	+19.81%	8.6B
BELLRING BRANDS, INC.	-6.80%	6.72B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-14.67%	5.04B
THE SIMPLY GOOD FOODS COMPANY	-6.54%	3.71B
BYHEALTH CO., LTD	-21.43%	3.13B
HERBALIFE LTD.	-23.20%	1.17B
XIAMEN KINGDOMWAY GROUP COMPANY	-17.45%	1.13B
JAMIESON WELLNESS INC.	-1.83%	944M
USANA HEALTH SCIENCES, INC.	-11.94%	899M

Special Foods & Wellbeing Products

Helixmith Co., Ltd

Equities

A084990

KR7084990001

Food Processing

Helixmith Co., Ltd announced that it has received KRW 20 billion in funding

Latest news about Helixmith Co., Ltd

Chart Helixmith Co., Ltd

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Special Foods & Wellbeing Products